In a few short years, excitement about groundbreaking anti-obesity drugs made Novo Nordisk Europe’s most highly valued company and Eli Lilly the biggest pharma group in the world. Just as quickly, investors are losing their appetite for the trade.
短短几年间，围绕突破性抗肥胖药物的兴奋就让诺和诺德(Novo Nordisk)成为欧洲估值最高的公司，让礼来(Eli Lilly)成为manbetx app苹果 最大的制药集团。但在同样迅速的时间内，投资者就对这一交易失去了兴趣。
您已阅读4%（350字），剩余96%（9005字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。